Robert J Riley

发表

Predictive ADMET studies, the challenges and the opportunities.

Andrew M Davis, Robert J Riley, A. Davis, 2004, Current opinion in chemical biology.

A new paradigm for navigating compound property related drug attrition.

Robert J Riley, Patrick Barton, P. Barton, 2016, Drug discovery today.

Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling

Robert J Riley, Claire E Wilson, R. Riley, 2015, Expert opinion on drug metabolism & toxicology.

Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.

Robert J Riley, James Bird, Douglas Ferguson, 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES

Robert J Riley, Steve Trigg, Dermot F McGinnity, 2005, Drug Metabolism and Disposition.

Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells

Jane R Kenny, Robert J Riley, Dermot F McGinnity, 2009, Drug Metabolism and Disposition.

THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES

Robert J Riley, Patrick Barton, R. Austin, 2005, Drug Metabolism and Disposition.

The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties.

Scott L Cockroft, Robert J Riley, Patrick Barton, 2002, Drug metabolism and disposition: the biological fate of chemicals.

The influence of DMPK as an integrated partner in modern drug discovery.

Robert J Riley, Iain J Martin, Anne E Cooper, 2002, Current drug metabolism.

EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE

Robert J Riley, Dermot F McGinnity, R. Urbanowicz, 2004, Drug Metabolism and Disposition.

Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption

Robert J Riley, Dermot F McGinnity, Rebecca Denton, 2011, Drug Metabolism and Disposition.

Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.

Matthew W D Perry, Emma Roe, Robert J Riley, 2012, Bioorganic & medicinal chemistry letters.

A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology.

Robert J Riley, R. Riley, K. Krausz, 2003, British journal of clinical pharmacology.

Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.

Peter J H Webborn, Robert J Riley, R. Riley, 2009, Molecular pharmaceutics.

Harmonised high throughput microsomal stability assay.

Robert J Riley, R. Riley, B. Williamson, 2017, Journal of pharmacological and toxicological methods.

Time-dependent CYP inhibition

Robert J Riley, Ken Grime, Richard Weaver, 2007, Expert opinion on drug metabolism & toxicology.

Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes

Peter J H Webborn, Robert J Riley, R. Riley, 2008, Drug Metabolism and Disposition.